



Working with us – Small molecule drug discovery

CSIRO supports early-stage drug discovery, focussing on target biology, synthetic and medicinal chemistry, in vitro and in vivo testing and process development for up-scale manufacturing

Our capabilities include:

- stem cell biology, virology and immunology.
- protein production, structural biology and biophysical, biochemical and cell biology assays.
- screening libraries, synthetic organic and medicinal chemistry, drug delivery and process development.

We work across a range of therapeutic areas including oncology, infectious disease, autoimmune conditions, vascular disease, ocular disease, parasitic infections and pain.

Support for SMEs

CSIRO offers start-ups and SMEs opportunities to initiate and facilitate their R&D programs through access to our world-class facilities and researchers. We also offer matched funding support and training and can help you navigate the research ecosystem.



Case study: Cancer Therapeutics CRC(CTx)

Over 13 years through the Cancer Therapeutics Cooperative Research Centre (CRC), CSIRO contributed to development of globally recognised Australian small molecule anticancer drug discovery projects, resulting in:

- new anticancer drugs in clinical trials.
- start-up of new Australian biotech companies.
- financial returns from licensing deals which continue to support Australia's drug discovery industry.

The CRC brought together biology target expertise and drug discovery capabilities from leading medical research institutes and universities together with commercial acumen from industry. CSIRO provided capabilities in protein production, biophysics as well as the structural biology that underpinned much of the IP developed between 2014 and 2020.

CSIRO continues to work with companies aiming to find cures for cancer.



Working with us –

Our capabilities in small molecule drug discovery and development

